meta
|
evidence
oncology
Living systematic review and meta-analysis
locally advanced (laHNSCC)
laHNSCC - (neo)adjuvant (NA)
laHNSCC - 1st line (L1)
1
laHNSCC - 2nd line (L2)
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab alone
versus all
vs non active control
vs placebo
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
Statistically conclusive or suggested result
Inconclusive results
Uncertain results
Safety results
laHNSCC - 1st line (L1)
locally advanced (laHNSCC)
laHNSCC - 1st line (L1)
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open